We recently described the design of Escherichia coli K12 and Salmonella enterica sv Typhimurium to display the gangliomannoside 3 (GM3) antigen on the cell surface [1] . We report here the fucosylation of modified lipooligosaccharide in a recombinant E.coli strain with a truncated lipid A core due to deletion of the core glycosyltransferases genes waaO and waaB. This truncated structure was used as a scaffold to assemble the Lewis Y motif by consequent action of the heterologously expressed β-1,4 galactosyltransferase LgtE (Neisseria gonorrheae), the β-1,3 N-acetylglucosaminyltransferase LgtA and the β-1,3 galactosyltransferase LgtB from Neisseria meningitidis, as well as the α-1,2 and α-1,3 fucosyltransferases FutC and FutA from Helicobacter pylori. We show the display of the Lewis Y structure by immunological and chemical analysis.
Introduction
Carbohydrates are common molecular tools to mediate interactions between cells. Eukaryotes as well as bacteria and archaea synthesise numerous oligo-and polysaccharide structures, many of which are located on the cell surface. In bacteria, surface carbohydrates are important structural motives involved in many biological processes including virulence, phage protection, and host immunity. The main classes of carbohydrate-containing extracellular compounds are capsular polysaccharides, lipo-oligo/polysaccharides, and to a certain extent, outer membrane glycoproteins [2, 3] . The unravelling of the respective biosynthetic pathways has opened new strategies to engineer bacterial surfaces. One aspect of this field of research is the engineering of non-pathogenic bacterial strains to display pathogen-related motifs. These newly generated strains can then be used to initiate and study an immune response against carbohydrate structures without any additional harmful effects of the pathogenic strain. Additionally, bacteria can be engineered to express and display carbohydrate motives of a mammalian host for subsequent use in pathogen neutralisation after infection of the host [4, 5] . The engineering of heterologous carbohydrate structures on bacterial cell surfaces in vivo requires several steps: The provision of a donor substrate for the glycosyltransferase(s), the availability of an acceptor structure and the possibility to export the in vivo created foreign carbohydrate structure to the cell surface. The last aspect often prevents the display of engineered oligosaccharides on the cell surface. For example, although the biosynthesis of the lipo-oligosaccharide core of Escherichia coli is well known, the details of the exportation pathway from the cytoplasm to the outermembrane are not completely elucidated. Recently, it could be demonstrated that LPS transport involves the periplasmic protein LptA, the cytosolic protein LptB and the inner membrane proteins LptC, LptF and LptG, which constitute an ABC transporter with accessory proteins [6] . The nascent LPS molecule is then targeted to the outer leaflet of the outer membrane by the outer membrane proteins LptD/LptE [7] [8] [9] .
To create an acceptor substrate for heterologously expressed glycosyltransferases, bacteria with a truncated LOS structure can be obtained by deletion of genes encoding glycosyltransferases involved in the first steps of the lipid A core synthesis. The heterologous expression of glycosyltransferases able to act on such truncated LOS of Escherichia coli R1 allowed surface display of globotriaose (Gb3), lac-N-neotetraose (LnNT), and gangliosides GM1 and GM3 [4] . The resulting strains were used as neutralizing bio-agents of the Shiga toxin (Stx) and enterotoxic E. coli [5] . Another possibility is to build the heterologous carbohydrate structure on the lipid linker undecaprenylphosphate, with a subsequent transfer of this structure to a full lipid A core by the O-antigen ligase WaaL. For example, the overexpression of Haemophilus influenzae genes encoding glycosyltransferases in E. coli resulted in the endogenous synthesis of a recombinant LOS carrying Haemophilus LPS motifs [10] . Altogether, these data show that the lipid A export system of E. coli has a certain flexibility towards its substrate and is able to transport foreign structures to the outer membrane. However, none of the chimeric LOS structures reported above contain fucose, an important monosaccharide involved in cell recognition. On the host side, fucose forms part of a target for a number of pathogens such as Pseudomonas aeruginosa, or Campylobacter jeujuni [11, 12] . On the bacterial side, fucose is for example present on the gastric pathogen Helicobacter pylori.
Our recent work focused on the glyco-engineering of E. coli to produce recombinant oligosaccharides [11] . The technology is based on the internalisation of β-galactosides such as lactose followed by endogenous glycosylation when glycosyltransferases from other bacteria were expressed recombinantly. With this system, we successively achieved the synthesis of fucosylated oligosaccharides including the human Lewis X and H antigens [13] [14] [15] [16] . Additionally, the co-expression of α1,2-and α1,3-fucosyltransferases of H. pylori led to the production of oligosaccharides carrying the Lewis Y antigen [17] , which is a structural motif of the lipooligosaccharide of H. pylori [18] , and a tumor-associated antigen in humans [19] .
In the present report, we addressed the fucosylation of the LOS of Escherichia coli K12 with α1,2-and α1,3-fucosyltransferases of H. pylori. A double mutant over-expressing a β-galactosyltransferase of Neisseria gonorrhoea was designed in order to exhibit a terminal lactosyl motif at the distal moiety of lipid A. The recombinant enzymes previously used in our lab to produce fucosylated oligosaccharides from lactose were over-expressed in that strain in order to glycosylate the lactosyl-lipidA core. Chemical analyses and immunological assays were performed and attested for synthesis and exportation of the Lewis Y epitope Fucα-2Galβ-4[Fucα-3] GlcNAcβ-3Gal (Fuc = fucose, Gal = galactose, GlcNAc = N-acetylglucosamine) amongst other glycoforms.
Materials and methods

Bacterial strains and growth conditions
A summary of bacterial strains used in this study can be found in Table 1 . Bacteria were grown in Luria-Bertani (LB) medium (10 g/l Bacto tryptone, 5 g/l Bacto yeast extracts, 5 g/l NaCl). LB agar plates were supplemented with 1.5% (w/v) agar. Antibiotics were used at the following final concentrations: Tetracyclin 10 μg/ml, ampicillin 100 μg/ml, kanamycin 50 μg/ml, chloramphenicol 25 μg/ml.
Construction of the E. coli K-12 ΔwcaJΔwaaOΔwaaB strain LPS1
To inactivate wcaJ, primers (a+b) ( Table 1) were used for PCR amplification of 0.64 kb of DNA flanking the 5′ end of wcaJ from JM107, whereas primers (c+d) were used for PCR amplification of 1.27 kb of DNA flanking the 3′ end of wcaJ. The reverse sequence of primer (c) was contained in primer (b), allowing a fusion of both DNA fragments by PCR amplification with primers (a+d). Fused DNA of 1.91 kb containing a truncated wcaJ was cloned into BamHI site of the suicide plasmid pKO3. The resulting recombinant suicide plasmid pKO3-J containing a truncated wcaJ sequence and flanking DNA to guaranty recombination was transformed into TA1 cells, mutants were obtained according to author's instructions [20] . Positive clones were screened by PCR with primers (a) and (c). The inactivation of waaO and waaB is described elsewhere [1] .
Construction of plasmids pSUlgtA and pSU-lgtAfutC Plasmid pLNT1T [16] was digested with NdeI to remove lgtB, thus ligated, providing pBBR-lgtA. LgtA was then obtained by KpnI and XbaI digestion for the cloning into pSU2718 to give pSU-lgtA. FutC was obtained by KpnI and SalI digestion of plasmid pEXT20futC [14] and subcloned into pBluescript KS, thus giving pBS-futC. This plasmid was then digested with XbaI to obtain futC flanked by two XbaI sites, allowing a cloning into XbaI site of pSU-A to give pSU-lgtAfutC.
Cell-based ELISA Bacterial cultures that had been induced overnight with 0.6 mM IPTG were equalized to 2 OD 600 /ml with PBS. Flat-bottom ELISA plates were coated with 50 μL of cells and fixed by addition of 20 μL of formaldehyde for 30 min at room temperature. Afterwards, the formaldehyde was removed and unspecific binding was blocked by addition of 1% (w/v) BSA in PBS for 1 h at room temperature. The blocking agent was then removed and the cells were incubated for 1 h at 4°C with anti-Lewis Y antibody (Abcam) in 0.1% (w/v) BSA in PBS. After four washing steps with 0.05% Tween-20/PBS, the bound anti-Lewis-Y antibody was detected by incubation of the cells with an anti-mouse-IgM-HRP conjugate (Santa Cruz) for 45 min at room temperature. Unbound HRPconjugate was washed away with 0.05% Tween-20/PBS in four washing steps before the cells were resuspended in 200 μl ABTS solution (2,2′-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid, final concentration 1 mM in 70 mM phosphocitrate buffer pH 4.2 with addition of 1% H 2 O 2 ). V max was determined by recording the color development at 405 nm for 5 min in a SpectraMaxPlus (Molecular Devices).
Electrophoretic analysis of chimeric LOS by SDS-PAGE and immunological detection
The equivalent of 1 OD 600 of exponentially growing induced cultures with 0.6 mM IPTG was pelleted and resuspended in 500 μl 0.065 M Tris-HCl pH 6.8, 2% SDS (w/v), 5% β-Mercaptoethanol (v/v), 10% Glycerin (v/v), 0.05% Bromophenol blue (w/v) and lysed for 5 min at 95°C. After cooling to room temperature, proteins were digested by addition of proteinase K (Roche, final concentration 0.4 mg/ml) for 1 h at 60°C. Equal volumes of each sample were then separated on a 17% Tris-Tricine-PAGE and stained with silver as described [26] .
To detect LewisY structures in the chimeric LOS after gel electrophoresis, a monoclonal anti-LewisY antibody (Abcam) was used. Bound anti-LewisY was visualised with a goat-anti-mouse-IgM-HRP conjugate (Santa Cruz) and ECL (Amersham) as recommended by the manufacturer. [27] , except that it was recovered from the phenol phase by precipitation with 6 volumes of diethyl ether/acetone (1:5 v/v) as described [28] .
Preparation of de-O-acylated LPS
De-O-acylation was obtained by conventional mild hydrazinolysis except that hydrazine-hydrate was used instead of anhydrous hydrazine. The solution (20 mg LOS/ml) was stirred at 37°C for 2 h. De-O-acylated LOS was recovered from the hydrazine phase by precipitation with 15 volumes of ice-cold acetone. The pellet was recovered by centrifugation, washed with acetone and air-dried.
Mass spectrometry analysis MALDI-MS spectra of the sample were obtained with an Autoflex Bruker MALDI-TOF spectrometer. DHB (2, 5-Dihydroxybenzoic acid, SIGMA) was used as a matrix. The De-O-acylated LOS sample was dissolved in water at a concentration of 0.4 mg/mL, DHB at 50 mg/ml in methanol. One μl of each solution was loaded and mixed directly on the target by the dried droplet method. The analysis was performed in the linear negative ion mode with an accelerating voltage of 20 kV and an extraction delay of 90-80 nsec. Spectra were calibrated externally using a peptides mix standard from Bruker Daltonics.
Methylation linkage analysis
The LOSs (about 70 mg) were degraded with 0.1 M sodium acetate buffer, pH 4.2, at 100°C for 4 h to cleave the acidlabile ketosidic linkage between the core OS and lipid A. The water-insoluble lipid A was removed by centrifugation at 20,000 g for 20 min. The oligosaccharide fraction was precipitated from the soluble phase by adding 4 vol of −20°C acetone [29] . Samples were centrifuged at 13,000 g at 4°C for 20 min, and the salt-containing 80% acetone supernatant was discarded. The pellet was dried, solubilised in dimethylsulfoxide, and methylated with methyl iodine [30] . Permethylated oligosaccharides were hydrolysed in 3 M trifluoroacetic acid for 3 h at 100°C. Methylated sugars were analysed after reduction using NaBD 4 and acetylation with an equal mixture of acetic anhydride and pyridine. Partially methylated alditol acetates (PMAA) were analysed by GC-MS using an agilent chromatograph 6850 equipped with a 5975C MS detector. The neutral sugars and the glucosamine derivatives were separated on a SP2380 column and a HP5-MS column, respectively.
Results
Engineered E. coli overexpressing fucosyltransferase-genes from H. pylori produced the Lewis Y epitope and presented it on the cell surface
In our previous work, a mutant of E. coli K12 synthesizing a glucose-terminal truncated lipid A core was prepared by inactivation of glycosyltransferases genes waaO and waaB [1] . To construct strains displaying fucose-containing structures, we additionally deleted wcaJ involved in the assembly of colanic acid synthesis, thus providing GDPfucose availability under over-expression of the positive regulator of the CPS operon (capsular polysaccharide) named Rcsa [16] . The resulting strain was termed LPS1. Five glycosyltransferase genes necessary for the display of the Lewis Y antigen from different bacterial sources were expressed heterologously: lgtE, encoding a β1,4-galactosyltransferase of Neisseria gonorrhoea reported to transfer to glucose in the LOS structure of N. gonorrhoea [31] ; lgtA from Neisseria meningitidis encoding a β1,3-N-acetylglucosaminyltranferase with galactose as an acceptor, and lgtB, encoding a β1,3-galactosyltranferase with N-acetylglucosamine as an acceptor, also from N. meningitidis [32] . In addition, futA and futC, encoding α1,3-and α1,2- (Fig. 1) . These data indicated the display of the Lewis Y motif at the surface of the recombinant strain LY.
In order to visualize glycosylation of the truncated LOS acceptor by apparent molecular weight increase of the LOS in gel electrophoresis, a time-course experiment was carried out with the recombinant strain expressing the glycosyltransferases necessary for display of the Lewis Y motif. Cell lysates of these cells were then prepared and analysed by Tris-Tricine polyacrylamide gel electrophoresis followed by silver stain (Fig. 2a) and immunoblot (Fig. 2b) . The addition of monosaccharides on the LOS acceptor structure was clearly visible by the appearance of bands with higher apparent molecular weight over time as can be seen in the silver nitrate stained gel which correlated with recognition by the anti-Lewis Y monoclonal antibody in the immunoblot analysis. Several bands of an apparent molecular weight intermediate of the truncated lipid A core and the Lewis Y carrying lipid A core could be observed in the silver nitrate staining (Fig. 2a) , which suggested some heterogeneity in the glycosylation profile, although a single band was detected by the antibody (Fig. 2b) .
Chemical analyses revealed presence but low abundance of Lewis Y motif due to the broad specificity of the α3-fucosyltransferase of H. pylori
In order to correlate the immunological description of the strains generated to a chemical characterization of recombinant LOSs, MALDI-TOF mass spectrometry analysis was conducted with de-O-acylated LOSs of the different E. coli strains. This technique was proven to be suitable to determine the relative abundance of bacterial LOSglycoforms [33] . In parallel, methylation linkage analyses were carried out with the de-O-acylated LOSs. Results are summarized in Table 2 and Fig. 3 . The de-O-acylated LOS sample of the LPS1 strain contained a main species at 2015.9 Da, fitting to the molecular composition P 3 -Glc-Hep 2 -Kdo 2 -lipid A as previously reported for this strain [1] . An additional species corresponding to P 3 -Glc-Hep 2 -Kdo 2 -PEtN-lipid A (+123 Da) was also observed (Fig. 3, uppermost panel) .
The spectra of the three recombinant strains H type II, LX, and LY showed progressively larger molecular weight LOS as a result of the overexpression of recombinant glycosyltransferase genes. All three strains overexpressed the genes encoding for LgtE, LgtA and LgtB, which are responsible for the synthesis of Galβ-3GlcNAcβ-3Galβ-4-Glc-P 3 -Glc-Hep 2 -Kdo 2 -lipid A by glycosylation of the truncated core present in the LPS1 strain. The MALDI-TOF spectra of the three strains (H type II, LX, LY) showed a common peak arising at 2542 Da (Fig. 3 ) from the addition of two hexoses (Hex) and one Nacetylhexosamine (HexNAc) to the truncated Glc-LOS of the LPS1 strain, compatible with an additional [GalGlcNAc-Gal] motif. An associated Galβ-3GlcNAcβ-3Galβ-4Glc-P 3 -Glc-Hep 2 -Kdo 2 -PEtN-lipid A species was also observed (2665 Da, Fig. 3) .
The chemical analysis of the H type II strain LOS sample. Which specifically expressed the α1,2-fucosyltransferase FutC in addition to LgtE, LgtA and LgtB contained a peak at 2687.5 Da corresponding to an additional fucose residue present (Fig. 3, second panel from top) , matching to the carbohydrate backbone [Fuc-Gal-GlcNAc-Gal-P 3 -Glc- (Table 2) confirmed the presence of a terminal fucose residue as well as 2-linked galactose, characterizing the motif Fucα-2Gal and therefore glycoform I (Fig. 4) . This is in agreement with the specificity of FutC on β-galactosides.
When the de-O-acylated LOS sample of LX strain, which specifically expressed the α1,3-fucosyltransferase FutA in addition to LgtE, LgtA and LgtB, was analysed by MALDI-TOF it resulted in a spectrum very similar to the one of the H type II strain, although the proportion of the mono-fucosylated species [Fuc-Gal-GlcNAc-Gal-P 3 -GlcHep 2 -Kdo 2 -lipidA] (and the corresponding PEtN-lipidA glycoform) was much higher (Fig. 3, second panel from  bottom) . The methylation analysis revealed the presence of a high amount of 3,4-linked glucose and a low amount of 3,4-linked N-acetylglucosamine. This indicated a fucosylation of the C3-OH of GlcNAc (in the lactosaminyl motif) but on the other hand of the Glc residue (in the lactosyl motif) as well, thereby demonstrating the presence of glycoforms II and III (see Fig. 4 ). These data fit to the known specificity of the fucosyltransferase FutA used in this study, which was reported to have a good activity on lactosyl as well as N-acetyllactosaminyl motifs of H type II acceptors [34] . A preferential fucosylation on glucose was also obtained when the same co-expressed enzymes acted on free lactose as an acceptor [16] . A small glycoform at m/ z 2838 Da (Fig. 3, second panel from bottom) corresponded to a difucosylated carbohydrate backbone [Fuc 2 -GalGlcNAc-Gal-P 3 -Glc-Hep 2 -Kdo 2 -lipidA], which meant that both the Glc and the GlcNAc residue of the Gal-GlcNAcGal-P 3 -Glc-Hep 2 -Kdo 2 -lipidA] backbone were fucosylated, leading to glycoform IV (Fig. 4) .
The LY strain used in our study combined the two α1,2-and α1,3-fucosyltransferases FutC and FutA, which had been expressed separately in the strains LX and H type II. When the de-O-acylated LOS sample of the LY strain was analysed, the MALDI-TOF spectrum obtained was comparable with the spectrum of the LX strain, but showed a slight increase of difucosylated forms (Fig. 3, lowest panel) . The methylation analysis revealed the combined derivative products of the α-1,2-fucosyltransferase action (2-linked Gal) and of the α-1,3-fucosyltransferase action (3,4-linked Glc/GlcNAc), thus corresponding to glycoforms V and VI, the last one bearing the Lewis Y antigen (Table 2 and Fig. 4 ).
Discussion
Our data show that fucosylation of the lipid A core of Escherichia coli K12 can be obtained by design of a suitable LOS mutant co-expressing various glycosyltransferases. This is the first report describing the endogenous fucosylation of the lipid A core of E coli. The human cell surface antigen Lewis Y was displayed on the bacterial cell surface of the LY strain as visible in a cell-based immunoassay using a monoclonal antibody raised against Lewis Y (Fig. 1) . The chemical analysis of de-O-acylated LOS showed that the Lewis Y structure was not predominant, since a major form carrying a fucose on glucose was also observed. These data can be explained by the reduced specificity of the α1,3-fucosyltransferase used in this study. A possibility to increase the expression of the Lewis Y epitope could include the use of a more specific fucosyltransferase. In this respect our bacterial system displaying fucosylated structures on the cell surface would enable researchers to sort clones (e.g. by fluorescence-activated cell sorting) exhibiting an improved Lewis Y expression after the molecular evolution of the α1,3-fucosyltransferase used. It is interesting to note that, although the α1,3-fucosyltransferase employed in this study shows relaxed specificity towards the acceptor substrate, we can assume that the configuration of the oligosaccharide product created in the E. coli cells by heterologous glycosyltransferase expression is corresponding to the configuration seen in the Lewis Y epitope e.g. on human blood cells as it is unlikely that recognition by the monoclonal antibody against the Lewis Y epitope would not be hindered by a Earlier studies in our lab also showed that the oligosaccharide product created by heterologous expression of the α1,3-fucosyltransferase as well as the other glycosyltransferases except the α1,2-fucosyltransferase could be shown to contain the wild type monosaccharide configuration by NMR when produced in a soluble form [15] .
The strains H type II and LX synthesized the group H-type 2 and the Lewis X oligosaccharide motifs, respectively, as judged by the chemical analysis of their respective LOS. The fucosylation on LOS was detected by lectinbased cell detection assays with the fucose-binding lectin of Ralstonia solanacearum [35] , but our attempt to make a specific detection with a Lewis X antibody was not successful.
The MALDI-TOF analysis suggests that all recombinant strains possess PEtN-modified lipid A core species. The PEtN substitution is normally not important in Escherichia coli K12, but has been associated with the outer membrane adaptation to environmental stress induced by divalent cations and some antibiotics [36, 37] . A possible explanation for the PEtN substitutions visible in our strains is that the chimeric glycosylation of the outer core affects the outer membrane stability, resulting in an induction of PEtN substitution of the lipid A core.
This work is a step forward in the glyco-mimicry engineering of bacteria. Lewis antigens are common host targets for pathogens to bind to, such as pathogenic C. jejuni, and P. aeruginosa [11, 12] . Competition experiments with our fucose-displaying non-pathogenic strains therefore might be a prelude to the design of new probiotic-based therapies. Furthermore, these strains present the researcher with the possibility to change the specificity of glycosyltransferases by molecular evolution and subsequent testing with lectins and cell sorting. In addition, our strains could in the future be used to study the interaction between host receptors with the mentioned carbohydrate structures on non-pathogenic bacteria, thereby enabling us to dissect the effects mediated by the carbohydrate structures from the ones mediated by other bacterial virulence factors.
